S. Evans

Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals

C. Hadjichrysanthou, F. de Wolf, R. Anderson, 2019, Scientific Reports.

The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease

C. Hadjichrysanthou, F. de Wolf, R. Anderson, 2020, Alzheimer's Research & Therapy.

Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies

C. Hadjichrysanthou, F. de Wolf, R. Anderson, 2018, Journal of Alzheimer's disease : JAD.

Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets

O. Lopez, D. Ames, C. Hadjichrysanthou, 2019, Alzheimer's & dementia.

The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?

C. Hadjichrysanthou, F. de Wolf, R. Anderson, 2018, European Journal of Epidemiology.

Cortisol, Amyloid-β, and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults.

S. Sindi, R. Perneczky, L. Middleton, 2019, Journal of Alzheimer's disease : JAD.

Why do so many clinical trials of therapies for Alzheimer's disease fail?

Christoforos Hadjichrysanthou, Roy M Anderson, R. Anderson, 2017, The Lancet.

The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease

C. Hadjichrysanthou, F. de Wolf, R. Anderson, 2020, Alzheimer's Research & Therapy.